X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs LUPIN LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES LUPIN LTD DIVIS LABORATORIES/
LUPIN LTD
 
P/E (TTM) x 32.2 161.5 20.0% View Chart
P/BV x 5.2 3.0 174.2% View Chart
Dividend Yield % 0.9 0.8 113.5%  

Financials

 DIVIS LABORATORIES   LUPIN LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
LUPIN LTD
Mar-17
DIVIS LABORATORIES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,2221,750 69.8%   
Low Rs7841,384 56.7%   
Sales per share (Unadj.) Rs153.1387.4 39.5%  
Earnings per share (Unadj.) Rs39.956.6 70.5%  
Cash flow per share (Unadj.) Rs44.676.8 58.0%  
Dividends per share (Unadj.) Rs10.007.50 133.3%  
Dividend yield (eoy) %1.00.5 208.3%  
Book value per share (Unadj.) Rs201.8298.9 67.5%  
Shares outstanding (eoy) m265.47451.58 58.8%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x6.64.0 162.0%   
Avg P/E ratio x25.127.7 90.8%  
P/CF ratio (eoy) x22.520.4 110.3%  
Price / Book Value ratio x5.05.2 94.8%  
Dividend payout %25.013.2 189.0%   
Avg Mkt Cap Rs m266,266707,513 37.6%   
No. of employees `0009.716.8 58.0%   
Total wages/salary Rs m4,68728,495 16.4%   
Avg. sales/employee Rs Th4,175.010,418.3 40.1%   
Avg. wages/employee Rs Th481.51,697.0 28.4%   
Avg. net profit/employee Rs Th1,089.31,523.0 71.5%   
INCOME DATA
Net Sales Rs m40,643174,943 23.2%  
Other income Rs m7491,065 70.3%   
Total revenues Rs m41,392176,008 23.5%   
Gross profit Rs m14,46044,931 32.2%  
Depreciation Rs m1,2339,122 13.5%   
Interest Rs m231,525 1.5%   
Profit before tax Rs m13,95335,349 39.5%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3499,785 34.2%   
Profit after tax Rs m10,60425,575 41.5%  
Gross profit margin %35.625.7 138.5%  
Effective tax rate %24.027.7 86.7%   
Net profit margin %26.114.6 178.5%  
BALANCE SHEET DATA
Current assets Rs m40,105119,542 33.5%   
Current liabilities Rs m6,59561,206 10.8%   
Net working cap to sales %82.533.3 247.3%  
Current ratio x6.12.0 311.4%  
Inventory Days Days11976 156.0%  
Debtors Days Days8190 89.8%  
Net fixed assets Rs m19,995131,660 15.2%   
Share capital Rs m531903 58.8%   
"Free" reserves Rs m53,043134,073 39.6%   
Net worth Rs m53,574134,976 39.7%   
Long term debt Rs m056,478 0.0%   
Total assets Rs m61,585266,073 23.1%  
Interest coverage x618.424.2 2,558.0%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.70.7 100.4%   
Return on assets %17.310.2 169.4%  
Return on equity %19.818.9 104.5%  
Return on capital %26.119.3 135.4%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38481,885 43.2%   
Fx outflow Rs m10,39921,506 48.4%   
Net fx Rs m24,98560,378 41.4%   
CASH FLOW
From Operations Rs m11,49341,148 27.9%  
From Investments Rs m-11,372-25,287 45.0%  
From Financial Activity Rs m-934,332 -2.1%  
Net Cashflow Rs m2820,193 0.1%  

Share Holding

Indian Promoters % 52.0 46.6 111.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.8 11.3 104.4%  
FIIs % 19.0 31.9 59.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.1 170.3%  
Shareholders   31,796 98,259 32.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  GSK PHARMA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 21, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS